by Jordyn Sava
With encouraging response rates and a well-tolerated safety profile seen in RAMP-201, experts are hopeful for the accelerated approval of avutometinib plus defactinib for low-grade serous ovarian cancer.
The combination of avutometinib (VS-6766) with defactinib (VS-6063), as … Read more
by Anita T. Shaffer
Efforts to target the folate metabolism network have entered a new stage, with the approval of a novel therapy directed at folate receptor–α and the potential for additional agents aimed at that target in solid tumors.… Read more
by Jason Harris
The FDA has asked Clovis Oncology to limit use of rucaparib (Rubraca) to second-line maintenance therapy for patients with recurrent ovarian cancer harboring BRCA mutations.1
The company is considering the FDA’s request. If the 2 sides
by Kristi Rosa
At the request of the FDA, GlaxoSmithKline (GSK) plc will restrict the second-line maintenance indication for niraparib (Zejula) to only the population of patients with recurrent ovarian cancer whose tumors harbor deleterious or suspected deleterious germline BRCA
Findings uncover possible drivers of recurrent breast and ovarian cancers among women carrying high-risk genetic mutations, pointing to methods to more effectively treat disease
PHILADELPHIA — Researchers at the University of Pennsylvania’s Basser Center for BRCA at the Abramson Cancer … Read more
by Megan Hollasch
Real-world data from a retrospective study showed that pembrolizumab combined with the anti-VEGF agent bevacizumab plus oral metronomic cyclophosphamide displayed minimal toxicity in a significant number of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal … Read more
by Mike Bassett
— Selpercatinib approved for advanced or metastatic solid tumors that progress on systemic therapy
The FDA granted accelerated approval to selpercatinib (Retevmo) for adults with locally advanced or metastatic solid tumors associated with RET gene fusions, the
… Read moreby Jordyn Sava
In an interview with Targeted Oncology during the EMSO Annual Congress, David O’Malley, MD, discussed the phase 1 study of ubamatamab in ovarian cancer.
Ubamatamab, a novel MUC16 antibody, demonstrated evidence of durable responses in patients with … Read more
by Victoria Johnson
ADP-A2M4CD8 will be evaluated in the phase 2 SURPASS-3 trial initiating in late 2022 or early 2023.
ADP-A2M4CD8, a CD8+ T-cell receptor (TCR) engineered T-cell therapy has yielded responses across a variety of MAGE-A4+ solid tumors, including
… Read moreCCR scientists have identified dozens of naturally occurring receptors that direct immune cells to tumors with mutations in p53, the most commonly mutated gene in human cancers. The research team, led by Steven Rosenberg, M.D., Ph.D., Chief of the … Read more
In an interview with Targeted Oncology, Erika P. Hamilton, MD, discussed the early clinical activity seen with DS-6000a in patients with advanced ovarian cancer or renal cell carcinoma with disease progression following standard of care treatment.
Interim data from a … Read more
by Kelly Irvin
It’s good to have all the facts when you decide whether to participate in a cancer drug clinical trial—even the ones that make you swallow hard and tear up.
To find clinical trials, please check out the … Read more
by the ASCO Post Staff
Today, 1 year after its founding, Break Through Cancer announced $50 million in grants to support several cutting-edge research projects using a novel “TeamLab” structure—designed to maximize interdisciplinary collaboration among researchers at Dana-Farber Cancer Institute, … Read more
by Ariana Pelosci
Data regarding different dosing strategies of elimusertib for advanced solid tumors with ATM alterations and other DNA damage repair gene defects display early efficacy of the therapy.
Patients with advanced solid tumors who have ATM gene alterations
by Hayley Virgil
Patients with pretreated ovarian cancer who are resistant to platinum-based chemotherapy may experience promising responses and disease control following treatment with nemvaleukin alfa and pembrolizumab.
Treatment with nemvaleukin alfa (ALKS 4230) plus pembrolizumab (Keytruda) yielded tumor responses
by Anne Doerr
A new study led by researchers at Yale Cancer Center and the University of Maryland Greenebaum Comprehensive Cancer Center shows ixabepilone plus bevacizumab (IXA+BEV) is a well-tolerated, effective combination for treatment of platinum/taxane-resistant ovarian cancer compared to … Read more
by Monica Janke, MD
In patients with ovarian cancer and pretreatment elevated CA-125 who achieved remission after frontline therapy, most recurrences are detected by rising CA-125 levels or symptoms.
In patients with ovarian cancer and pretreatment elevated CA-125 who achieved
by Kristi Rosa
The FolRα-targeted antibody-drug conjugate STRO-002 was found to elicit encouraging responses in heavily pretreated patients with advanced ovarian cancer.
The FolRα-targeted antibody-drug conjugate (ADC) STRO-002 was found to elicit encouraging responses in heavily pretreated patients with advanced
by Sucharita Mistry, PhD
Cytoreductive surgery followed by chemotherapy can prolong overall survival (OS), compared with chemotherapy alone, in certain patients with relapsed ovarian cancer, according to results from the DESKTOP III trial published in the New England Journal of … Read more
by Nichole Tucker
Top-line results from the phase 3 SORAYA study show promise for mirvetuximab in patients with FRα-high platinum-resistant ovarian cancer.
Single-agent mirvetuximab soravtansine (mirvetuximab; IMGN853) has demonstrated clinically meaningful benefit in patients with late receptor alpha (FRα)-high platinum-resistant
